PepSavvySearch peptides

Search peptides

Popular peptides
↑ ↓ Navigate ↵ OpenBrowse all peptides
Saved0
All peptidesAdipotide
Metabolic

Adipotide

Adipose-vascular targeting peptidomimetic (prohibitin-TP01)

Lab studiesBody-fat reduction2

Investigational; no FDA-approved adipotide formulation.

What does it do?

Prohibitin-TP01 targets fat-tissue vasculature. Primate fat loss came with kidney injury signals; human benefit is unestablished.

Approved & studied uses

Adipose-vascular targeting

2

Experimental obesity research; the exact compound and species matter.

Community uses Reported, unvalidated

Weight / metabolism

13

Primate fat-mass reduction and improved insulin responses; not human efficacy.

Appetite

13

Peripheral mechanism rather than established appetite suppression.

Reasons people report using it; these do not establish benefit.13

Evidence limits

View research →

Human efficacy and a safe dose are unverified.2

3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Kidney toxicity signal

Reversible renal proximal-tubule changes occurred in primate experiments.3

Investigational; no FDA-approved adipotide formulation.

Molecular information

Amino-acid sequence

An exact sequence has not been verified for this formulation.

LengthNot independently verified
Molecular weight · DaNot independently verified for the exact supplied form
Formula, sequence notation & identity
Molecular formulaNot independently verified for the exact supplied form4

Adipose-vascular targeting peptidomimetic (prohibitin-TP01)

Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.

Pharmacokinetics

How long does it stay in the body?

Reported half-lifeNo verified human estimate4

No numerical curve is shown without an exact compound, formulation and human-route match.

No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.

What to expect

Study outcomes

Newer research uses a different analogue

The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.2

Primate weight loss with renal effects

Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.3

Reported timelines

Reference & community

Weeks 1–2 / 2–4

Reference sequence: abdominal circumference then fat/weight changes; possible rebound after stopping. Not validated human timelines.13

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Primary goal

Fat loss100%

Number of responses to this question: not disclosed.

Source & limitations

The source displays “95 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

  • Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
  • The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
  • Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
  • Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
  • This is a dated snapshot, not a live survey or current recommendation.
Checked 2026-10-12Poll source ↗
Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

1 row

Scroll to compare all columns →

One row for each documented route and dose or dose range
RouteDoseFrequencyGoal / evidenceDurationReferences
SubQSubQ (escalating tiers)0.10–0.75 mg/kgOnce dailyDose‑finding (research)Reference report28 days13

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports13

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period
28 days
Break
≥4 weeks
Reported timing

Consistent daily timing; monitor hydration

Animal and cell protocols 2

Laboratory exposures cannot establish a human dose.

2 rows

Scroll to compare all columns →

Animal and cell exposures
RouteDoseFrequencyGoal / evidenceDurationReferences
SubQSubcutaneous0.43 mg/kgDailyFixed-dose primate experimentAnimals28 days3
SubQ0.43 mg/kgOnce dailyPrimate research replicationReference report28 days13

Side effects & safety

Kidney toxicity signal

Reversible renal proximal-tubule changes occurred in primate experiments.

3

Additional reported cautions

Reference reports13

Kidneys

Primate proximal-tubule injury, creatinine/electrolyte changes; reduced urine or sustained abnormalities need assessment.

Other symptoms

Severe injection/systemic reactions or unexpected toxicity.

Pregnancy

Pregnancy/lactation safety unstudied.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

9 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Semaglutide

Caution reported

GI/dehydration and renal concerns.13

Reference report · Pep-Pedia label: Monitor Combination

Tirzepatide

Caution reported

Volume/electrolyte and renal concerns.13

Reference report · Pep-Pedia label: Monitor Combination

CJC-1295 / Ipamorelin

Caution reported

Metabolic/body-composition confounding.13

Reference report · Pep-Pedia label: Use Caution

Nephrotoxic drugs: NSAIDs / aminoglycosides

Avoidance reported

Potential additional kidney injury.13

Reference report · Evidence context: Avoid claim

Cagrilintide

Unverified pairing

No combination data.13

Reference report · Evidence context: Unknown

AOD-9604

Unverified pairing

No combination data.13

Reference report · Evidence context: Unknown

BPC-157

Unverified pairing

Different targets do not establish safety.13

Reference report · Pep-Pedia label: Compatible

Melanotan II

Unverified pairing

Theoretical vascular/blood-pressure concerns.13

Reference report · Pep-Pedia label: Requires Timing

Other medicines and research compounds

Not established

No clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.4

Research context

Reconstitution

Product-specific information required

No universal bacteriostatic-water volume or validated preparation method is established for this entry.4

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.

Solvents mentioned
Bacteriostatic water
Reported parameters
Source temperature: 2–8°C.

The source describes gentle mixing and avoiding vigorous shaking.

13
Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceIntact Lyophilized CakeReported appearanceClear SolutionReported variationMinor ClumpingReported concernCollapsed/Moist CakeReported concernCloudiness/Precipitate
13

Available forms

No verified packaging examples included.

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.13

Full storage notes from Pep-Pedia13
Injectable

2–8°C

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Research findings

Preclinical
Compound identity & other names

An experimental compound designed to damage blood vessels supporting white adipose tissue. Animal weight-loss findings must be considered alongside kidney toxicity and the absence of verified human efficacy.

Other names: Adipotide (Prohibitin‑TP01)

Investigational; no FDA-approved adipotide formulation.

How it may work

A vascular-targeting sequence delivers a mitochondrial-disrupting motif, killing targeted endothelial cells.13

Newer research uses a different analogue

The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.

2

Primate weight loss with renal effects

Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.

3
Research areas and evidence gaps

Adipose-vascular targeting. Experimental obesity research; the exact compound and species matter.2

  • Human efficacy and a safe dose are unverified.
  • Research-market product identity, purity and formulation cannot be established from a publication.
Community reports Unvalidated

Pep-Pedia describes community interest and schedules; these are secondary reports, not measured clinical outcomes.4

No representative survey, independently verified products, or controlled outcomes.

Search coverage and review status

The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.

Checked
2026-10-12
Search
adipotide prohibitin TP01 2025 2026 study site:pubmed.ncbi.nlm.nih.gov
Catalog
Pep-Pedia ↗ · 10 listed references retained
  • Targeted search, not an exhaustive systematic review.
  • Bibliography-only entries are retained for traceability and are not treated as verified findings.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

13 sources

1Obese rhesus macaques – fixed-dose efficacy & safety; dose-finding (2011)Preclinical study · 2011 · pmc.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

Primate experiment found weight and fat loss with reversible renal proximal-tubule changes; no human efficacy conclusion.

Pep-Pedia bibliography · Checked 2026-10-12

Original source
2Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on ObesityPreclinical study · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

2025 mouse study concerns a modified prohibitin-targeting analogue, not a human trial of adipotide.

Newer research uses a different analogue

The 2025 mixed-chirality study evaluated a modified prohibitin-targeting compound in obese mice. It does not verify adipotide efficacy, preparation or dosing in people.

Pep-Pedia bibliography · Checked 2026-10-12

Original source
3Adipotide in obese Old World monkeysPreclinical study · 2011 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

Primate experiment found weight and fat loss with reversible renal proximal-tubule changes; no human efficacy conclusion.

Primate weight loss with renal effects

Obese monkeys lost weight and white adipose tissue; renal proximal-tubule function changed. The study does not establish human safety.

Additional research · Checked 2026-10-12

Original source
4Pep-Pedia: Adipotide — community referenceCommunity · 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.

Original source
5Human adipose targeting – imaging validation (2018)Research reference · 2018 · journals.plos.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: A CKGGRAKDC imaging probe targeted white adipose tissue. Probe localization does not establish adipotide efficacy or safety.

Reported population / model
Human adipose tissue (ex vivo) & mouse in vivo

Reported study details
CKGGRAKDC MRI probe · Single/short courses · Specific WAT targeting demonstrated

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study
6First-in-man phase 1 evaluation of Prohibitin-TP01 (NCT01262664)Trial registry · Accessed 2026 · clinicaltrials.govPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The small dose-escalation program ended before producing an efficacy result; it does not demonstrate human weight-loss benefit.

Reported population / model
Adults with metastatic prostate cancer & obesity

Reported study details
Subcutaneous, dose‑escalation · Early termination; limited enrollment

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study
7Reversal of obesity by targeted ablation of adipose tissueResearch reference · Accessed 2026 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Targeted vascular-cell death accompanied approximately 30% weight reduction in obese mice over four weeks.

Reported population / model
Mice (diet‑induced obesity)

Reported study details
CKGGRAKDC‑GG‑D(KLAKLAK)2 · Daily x 4 weeks · ~30% weight reduction; adipose vascular apoptosis; metabolic normalization

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study
8Comment on: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysResearch reference · Accessed 2026 · science.orgLinked reference · Not independently reviewed
REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source
9Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissueResearch reference · Accessed 2026 · ncbi.nlm.nih.govLinked reference · Not independently reviewed
REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source
10Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug deliveryResearch reference · Accessed 2026 · sciencedirect.comLinked reference · Not independently reviewed
REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source
11Prohibitin ligands in cell death and survival: mode of action and therapeutic potentialResearch reference · Accessed 2026 · cell.comLinked reference · Not independently reviewed
REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source
12Adipose tissue-targeting nanomedicines for obesity pharmacotherapyResearch reference · Accessed 2026 · pubmed.ncbi.nlm.nih.govLinked reference · Not independently reviewed
REFERENCE NOTE

Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.

Pep-Pedia bibliography · Checked 2026-10-12

Listed source
13Pep-Pedia: Adipotide — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source
Source details